Structure, substrate recognition and reactivity of Leishmania major mevalonate kinase
© Sgraja et al; licensee BioMed Central Ltd. 2007
Received: 15 November 2006
Accepted: 30 March 2007
Published: 30 March 2007
Isoprenoid precursor synthesis via the mevalonate route in humans and pathogenic trypanosomatids is an important metabolic pathway. There is however, only limited information available on the structure and reactivity of the component enzymes in trypanosomatids. Since isoprenoid biosynthesis is essential for trypanosomatid viability and may provide new targets for therapeutic intervention it is important to characterize the pathway components.
Putative mevalonate kinase encoding genes from Leishmania major (Lm MK) and Trypanosoma brucei (Tb MK) have been cloned, over-expressed in and proteins isolated from procyclic-form T. brucei. A highly sensitive radioactive assay was developed and shows ATP-dependent phosphorylation of mevalonate. Apo and (R)-mevalonate bound crystal structures of Lm MK, from a bacterial expression system, have been determined to high resolution providing, for the first time, information concerning binding of mevalonate to an MK. The mevalonate binds in a deep cavity lined by highly conserved residues. His25 is key for binding and for discrimination of (R)- over (S)-mevalonate, with the main chain amide interacting with the C3 hydroxyl group of (R)-mevalonate, and the side chain contributing, together with Val202 and Thr283, to the construction of a hydrophobic binding site for the C3 methyl substituent. The C5 hydroxyl, where phosphorylation occurs, points towards catalytic residues, Lys18 and Asp155. The activity of Lm MK was significantly reduced compared to MK from other species and we were unable to obtain ATP-binding data. Comparisons with the rat MK:ATP complex were used to investigate how this substrate might bind. In Lm MK, helix α2 and the preceding polypeptide adopt a conformation, not seen in related kinase structures, impeding access to the nucleotide triphosphate binding site suggesting that a conformational rearrangement is required to allow ATP binding.
Our new structural information, consistent with data on homologous enzymes allows a detailed description of how mevalonate is recognized and positioned for catalysis in MK. The mevalonate-binding site is highly conserved yet the ATP-binding site is structurally distinct in Lm MK. We are unable to provide a definitive explanation for the low activity of recombinant protein isolated from a bacterial expression system compared to material isolated from procyclic-form Trypanosoma brucei.
The biosynthesis of the isoprenoid precursors isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) is essential for prokaryotic and eukaryotic organisms. These ubiquitous compounds are utilized in the construction of numerous natural products including dolichols, sterols, terpenes and ubiquinones which contribute to myriad biological functions including hormone-based signaling, electron transport in respiration, apoptosis, meiosis and photosynthesis . Two distinct pathways have evolved to provide a pool of the precursors. In plant chloroplasts, algae, most eubacteria and apicomplexans, IPP and DMAPP are synthesized through the deoxyxylulose phosphate (DOXP) pathway, so named after an intermediate [2–4]. Alternatively, the mevalonate (MVA) pathway supplies these precursors in eukaryotes, archaea, a few eubacteria, in the cytosol of plants and of particular interest to us parasites of the genus Trypanosoma and Leishmania [4, 5].
The MVA pathway starts with condensation of three acetyl-CoA molecules to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA), which is reduced to (R)-MVA by HMG-CoA reductase. Next, two kinases phosphorylate (R)-MVA to (R)-MVA 5-diphosphate. This compound is subsequently decarboxylated to IPP and IPP isomerase then produces DMAPP from some of the IPP pool. The two phosphorylation steps and the decarboxylation are carried out in ATP-dependent reactions by the structurally related mevalonate kinase (MK), phosphomevalonate kinase (PMK) and mevalonate 5-diphosphate decarboxylase (MDD) respectively.
We have initiated studies of MVA pathway enzymes in protozoan trypanosomatids, parasites that cause severe diseases of humans and livestock. In Africa, T. brucei infection results in sleeping sickness while in South and Central America, T. cruzi causes Chagas' disease . Protozoans of the genus Leishmania, found throughout tropical and sub-tropical areas, are responsible for cutaneous, mucocutaneous and visceral forms of disease . Visceral leishmaniasis and trypanosomiasis are fatal if untreated and since the availability of effective drugs is limited, there is an urgent need to develop improved therapies. In support of such an effort it is important to achieve a comprehensive understanding of parasite metabolism, and to delineate aspects that are similar to the host from those that, by virtue of significant differences, might provide therapeutic opportunities.
First it was important to prove that the putative genes do indeed encode a functional MK. Assay of L. major MK (Lm MK) and T. brucei MK (Tb MK) derived from procyclic-form T. brucei show enzyme activity, and at a greatly enhanced level compared to Lm MK derived from a bacterial expression system. High-resolution crystal structures of Lm MK are reported and provide, for the first time, insight into the binding of substrate by any MK. There are significant structural differences at the ATP- binding site compared to other GHMP kinases. Consideration of previously published kinetic data on MK, derived from different species, and comparisons allows us to describe generic aspects of MK specificity and mechanism.
Results and discussion
Enzyme activity of Lm MK and Tb MK
The gene assigned as encoding a putative Lm MK was cloned into an Escherichia coli expression system and yielded 30 mg/L of purified protein. A coupled spectrophotometric assay has been successfully applied to analyze wild type and mutant MK enzymes from different species [10, 15–18]. However, no activity was observed for recombinant Lm MK using this method although the control experiment with Mj MK agreed well with literature values (data not shown). In a further experiment, the fluorescent ATP analogue 2'(3')-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate (TNP-ATP) was used to investigate ATP binding following an established protocol . In the presence of Lm MK, however, no enhancement in fluorescence could be detected compared to free TNP-ATP indicating that the derivative does not effectively bind the recombinant Lm MK (data not shown). This observation is consistent with the conformation of the ATP-binding site observed in the crystal structure and will be discussed later.
We considered the possibility that recombinant Lm MK activity might be too low for the spectrophotometric assay and so developed a more sensitive, radioactive assay. Activity of Lm MK was observed after incubation of the enzyme with radiolabeled [3H] (R)-MVA and ATP. After two hours, 22 pmoles of the 83.3 pmoles of [3H] (R)-MVA present were converted to [3H] (R)-MVA 5-phosphate, a turnover rate of 26 % or 1.6 pmol/min/mg.
SeMet Lm MK
Lm MK:R-MVA complex
a, b, c (Å),
41.3, 88.5, 88.2
41.2, 88.4, 87.7
Resolution range (Å)
R- merge (%)b
r.m.s.d. bond lengths (Å)
r.m.s.d. bond angles (°)
Wilson B value (Å2)
Number of atoms
Average B values (Å2)
Most favored (%)
Additional allowed (%)
Disallowed region (%)d
There are two molecules in the asymmetric unit (A and B) related by a non-crystallographic (NCS) two-fold axis of symmetry and the surface area between the two is 930 Å2 per molecule, only 6% of the total surface area of the protein. Such a low value is consistent with results from gel filtration and ultracentrifugation experiments that indicate Lm MK is a monomer in solution. Molecules A and B overlay with an r.m.s.d. of 1.2 Å for all atoms. Minor differences are observed in the conformation of the three C-terminal residues, several flexible residues at the N-terminal end of α6 and loop regions following β5 and α2. Molecule A of Lm MK binds the substrate and overlays on the apo-enzyme molecule A with an r.m.s.d. of 0.7 Å for all atoms. This indicates that there no large-scale conformational changes result from substrate binding and the molecules are so similar that it is only necessary to detail molecule A.
That Lm MK presents a monomer in solution makes it different from rat and human MK, which are reported to be dimeric [9, 10]. The crystal structure of the rat enzyme has a monomer in the asymmetric unit and a crystallographic two-fold axis of symmetry generates an extended dimer . The alignment of the two molecules in the asymmetric unit of Lm MK is similar to that of the rat enzyme in that an extended structure results. However, the orientation of the molecules is very different (not shown).
The GHMP kinase fold and three conserved motifs
The ATP-binding site of Lm MK is distinct from related enzymes
In CDPME kinase  and HSK, [22, 23] a helical insert also occurs before the α-helix equivalent to Lm MK α2, and similar to Rn MK, is placed to configure an open ATP binding site. Here, CDPME kinase and HSK carry residues that bind the ATP adenine in the less common syn conformation with respect to the ribose. In Streptococcus pneumoniae PMK  the polypeptide conformation also produces an open cavity into which ATP binds. In this case a segment of the polypeptide around the ATP-binding site is absent from the structural model due to disorder, and this implies a degree of conformational flexibility. Kinetic studies with Enterococcus faecalis MK indicate that GTP and CTP can also serve as substrates . To investigate if such promiscuous substrate utilization also applied to Lm MK we tested the same compounds in the enzyme assay and also by co-crystallization in the absence and presence of (R)-MVA. In the latter case, to prevent possible turnover of the substrate we used the non-hydrolysable guanosine 5'-(β,γ-imido) triphosphate and CDP. Despite our efforts, extending to the complete structural analysis of several diffraction datasets (not shown), we were unable to obtain a binary structure of Lm MK in complex with ATP, any nucleotide, or a ternary dead-end complex.
To model ATP binding, the structures of Lm MK and the Rn MK:ATP binary complex were superimposed. In the Rn MK:ATP complex, the adenine is anti with respect to the ribose. The β and γ-phosphoryl groups together with Ser146 and Glu193 coordinate a Mg2+. In Lm MK the modeled adenine and ribose groups clash with the side chains of Tyr67, Lys71 and Glu74 at the N-terminal end of α2, Arg61 and Gln75 in the preceding loop region and Tyr147 in α4. These residues are positioned by a network of hydrogen bonding interactions, some mediated by water molecules. As discussed, the polypeptide conformation at the N-terminal segment of α2 and in the preceding loop is distinct from other MK structures and reduces access to the ATP binding site. The ATP-binding cavity in Rn MK, in contrast, is more open and the nucleotide is embedded into an environment with significant hydrophobic character. Conformational changes would have to occur, a number of hydrogen bonds would have to be disrupted and water molecules displaced to facilitate ATP binding by Lm MK as represented by the crystal structure.
The triphosphate moiety is placed to interact with the glycine-rich loop of the ATP-binding motif 2 in Lm MK. The β-phosphoryl group of ATP most likely interacts with Ser111 and Ser112, the latter a residue invariant in MK sequences, corresponding to Ser146 in Rn MK, the serine that participates in Mg2+ coordination. The other residue involved in cation binding (Glu193 in Rn MK) is conserved (Glu144) in Lm MK and so conservation of the triphosphate positioning and interaction with MKs is likely. The model positions the γ-phosphoryl group in proximity to the strictly conserved catalytic residues Lys18 and Asp155 of Lm MK and the C5 hydroxyl group of substrate.
Binding and recognition of mevalonate
Site-directed mutagenesis studies highlight the importance of the strictly conserved Glu24, His25 and Ser152 (Lm MK numbering) in MK. The replacement of the histidine by leucine or tyrosine significantly reduced activity of human MK whereas a lysine mutant did not fold correctly . Houten et al. reported that a His25Pro mutant has no detectable MK activity . In Lm MK, the side chain of His25 forms hydrogen-bonding interactions to its own main chain carbonyl, via a water molecule, and to the carbonyl group of Thr283, a residue in motif 3. In turn the side chain of Thr283 is held in place by a hydrogen bond with Thr198 (Figure 7). The preceding residue Glu24 participates in a salt bridge interaction with Lys279. Such interactions, help to force the main chain between Glu24 and His25 into a strained conformation, with a φ/ψ combination of 75/-45°, directing the amide group towards the substrate. The corresponding histidine and glutamate residues in Mj MK and Rn MK are located at nearly identical positions, but there is a peptide-flip compared to Lm MK so that the carbonyl not the main chain amide is directed towards the substrate-binding site. A peptide-flip does not accompany substrate binding since apo-Lm MK molecules retain the strained conformation. The conformation in other MK structures may be a consequence of analyses at medium resolution. The strictly conserved Glu24 is also important for stability. Mutations of the equivalent residue in human MK (Glu19Ala and Glu19Gln) destabilize the enzyme while a Glu19Asp change only slightly decreased activity . The placement of an acidic side chain to interact with the nearby lysine (Lys330 in rat and human sequences) is therefore beneficial for function. Mutation of Ser201, equivalent to Ser152 in Lm MK, to alanine in human MK leads to a 100-fold decrease in binding affinity for substrate so proving an important role in substrate binding . Ser152 OG also contributes to forming a hydrogen-bonding network, with the amide group of Ala154 and via water molecules, to stabilize the position of the catalytic Asp155 (not shown).
Fu et al.  and Yang et al.  modeled (R)-MVA into Mj MK and Rn MK respectively, and suggested a different binding mode compared to the experimentally determined complex reported here. They proposed, independently, that the substrate carboxylate interacts with an arginine (Arg241 or Arg201 in Rn MK and Mj MK respectively) and main chain amides contributed from motif 3. Although the guanidinium groups of Arg241 and Arg201 are similarly placed in the Rn MK and Mj MK structures, in Lm MK this is Ala196. The lack of conservation of an arginine at this position in MK sequences has already been discussed .
In this section, we have described the contributions and importance of 14 residues to the binding of substrate in the Lm MK:(R)-MVA complex either by direct or solvent mediated interactions, or by creating the binding site. These residues are depicted in Figure 7 together with selected hydrogen bonding interactions. Twelve of these residues are strictly conserved in mammalian MK sequences. The two exceptions are Arg169, which is equivalent to Gln218 and is a conservative change, and Thr283, equivalent to Ala334. This high degree of conservation in the substrate-binding site suggests that the substrate is bound to MKs in a similar conformation compared to (R)-MVA in Lm MK.
The catalytic mechanism
In the Lm MK:(R)-MVA complex, the substrate C5 hydroxyl group is directed towards the side chains of Lys18 (~4 Å) and Asp155 (~5 Å) as well as the γ-phosphoryl of the modeled ATP (~6 Å). The positions of the strictly conserved lysine/aspartate pair are nearly identical in Lm MK, Mj MK and Rn MK. In kinetic studies of human MK, no significant activity of the Asp155Ala and Asp155Asn mutants was observed and a replacement of the basic Lys18 by methionine resulted in a 56-fold decrease of Vmax in Rn MK . Asp155 acts as a catalytic base and abstracts the proton from the C5 hydroxyl group of (R)-MVA to generate a potent nucleophilic alkoxide. The p Ka of the C5 hydroxyl group must be lowered in order for proton abstraction to occur, a process required to generate a nucleophilic alkoxide. Presumably the basic Lys18 is primarily responsible for lowering the p Ka and perhaps also stabilizing the alkoxide. Once the ATP is in place then the C5 alkoxide will attack and acquire the γ-phosphoryl group. A pentacoordinate transition state is likely and may be stabilized by Lys18 and the presence of a divalent cation, as commonly observed in many kinases.
Our study reveals, for the first time, MK activity in trypanosomatids. High-resolution crystal structures of Lm MK have been determined and provide the first experimentally derived model for any MK in complex with mevalonate. The structure reveals how this substrate binds, the structural basis for chiral discrimination of (R)- against (S)-form MVA and is consistent with previously published biochemical data regarding mechanism. The enzyme, not surprisingly displays the GHMP kinase fold and structural overlay indicates close similarities to Rn MK for most of the structure. However, comparisons reveal a significant difference at the ATP-binding site that may help explain the low activity of recombinant Lm MK and our inability to obtain structural information on an ATP complex. Sequence comparisons suggest that the β3-α2 loop and α2 segments, including many of the hydrogen bonding interactions in Lm MK are conserved in other trypanosomatid enzymes, Tb MK and Tc MK. As Lm MK and Tb MK expressed in procyclic-form T. brucei exhibit a greatly enhanced enzyme activity compared to the recombinant Lm MK, it is possible that some parasite specific factor may influence the catalytic reaction and further studies are required to investigate such a hypothesis.
The high degree of conservation between trypanosomatid and mammalian MKs suggests that it would be difficult to develop a small molecule that would selectively inhibit the parasite enzyme by interacting within the mevalonate-binding site. The differences observed in the ATP-binding sites might be exploitable for structure-based inhibitor design but a decision would best be taken when a structure of a trypanosomatid MK in complex with ATP has been determined.
Cloning, expression, purification of Lm MK for biophysical characterization
The putative gene encoding Lm MK (UniProt entry Q4Q6K7) was isolated from genomic DNA by PCR with forward 5'-CATATG TCTAAGCCCGTCAAGAGC-3' and reverse 5'-CTCGAG TTAT AGGTTCGACGCGGCG-3' primers containing Nde I and Xho I restriction sites respectively (underlined). The gene was cloned into the pCR blunt II TOPO vector (Invitrogen) then subcloned into the pET15b vector (Novagen). The resulting plasmid was transformed into E. coli BL21 (DE3) (Stratagene). The His-tagged protein was produced overnight at 30°C in LB medium containing ampicillin (100 mg/L) after induction with 1 mM isopropyl-β-D-thiogalactopyranoside. Cells, suspended in 50 mM Tris·HCl pH 8.5, 250 mM NaCl and 3 mM β-mercaptoethanol, were lysed at a pressure of 25 Kpsi (One Shot, Constant Cell Disruptions Systems) and the extract clarified by centrifugation (20,000 g, 30 min, 4°C). The supernatant was loaded onto a nickel chelating chromatography column (GE Healthcare) and eluted with a linear gradient from 70 to 800 mM imidazole. The His-tag was removed from Lm MK by digestion with thrombin for 6 h at 4°C. After dialysis against 50 mM Tris·HCl pH 7.7, 50 mM NaCl and 1 mM DTT, the enzyme was purified further by anion exchange chromatography and pooled fractions dialyzed against 10 mM Tris·HCl pH 8.5, 20 mM NaCl and 1 mM DTT. The protein was concentrated by centrifugation with a VivaSpin 20 MW cutoff 10,000 Da (Vivascience) and the protein concentration determined spectrophotometrically using an extinction coefficient of 28,000 M-1 cm-1 (280 nm).
For the production of SeMet Lm MK, the plasmid was transformed into E. coli strain B834 (Stratagene). Bacteria were grown in M9 medium, which was supplemented with 4 mg/L FeSO4·7H2O and 0.5 g/L each of adenine, guanosine, thymine and uracil. In addition, 40 mg/L of the usual amino acids except methionine, which was replaced by 100 mg/L L-SeMet (Sigma-Aldrich), were added. Protein production and purification was performed according to the protocol described for the native enzyme. Full incorporation of SeMet was confirmed by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (data not shown).
Cloning of T. brucei and L. major MK genes for ligation into the pLew 82 vector
Putative MK genes were identified in T. brucei (entry Q4Q6K7 in the UniProt database) and L. major genome databases (see above) in advance of annotation (Sanger Centre) using the S. cerevisiae gene sequence as the query. The open reading frame encoding Tb MK was amplified from T. brucei genomic DNA using forward and reverse primers 5'-GAGGAGAAGCTT ATGCACGTGGCTGTTAAGGAC-3' and 5'-TGCTTAATTAA TAGCTTACTTCCGCCGGGCTG-3' containing Hin dIII and Pac I restriction sites respectively (underlined). The open reading frame encoding Lm MK was amplified from L. major genomic DNA using the forward and reverse primers 5'- GAGGAGAAGCTT ATGTCCGTTTTTTTCGCTGTGACT-3' and 5'- TGCTTAATTAA TAGGTTCGACGCGGCGGACGGCTG-3' containing Hin dIII and Pac I restriction sites respectively (underlined). Bands of the expected size of ~ 1 Kb for both genes were amplified using Pfu polymerase, purified (QIAquick PCR purification kit, Qiagen) and cloned into pCR-Blunt II TOPO (Invitrogen). The ORFs were excised then ligated into the tetracycline inducible expression vector pLew82 , which integrates a C-terminal HA-epitope tag.
Cultivation and genetic modification of T. brucei
Procyclic form T. brucei strain 427, previously modified to express T7 polymerase and the tetracycline repressor protein, were grown in SDM-79 media supplemented with 5% sodium bicarbonate and the appropriate drug selection, at 28°C with 5 % CO2 as described elsewhere [29, 30]. Mid-log cells were electroporated with 50 μg of Not 1-linearized pLew82 plasmids in a total volume of 400 μL of cytomix buffer. Transfected parasites were selected in medium containing phleomycin (2.5 μg/mL) to obtain the cell lines TbMK-HATi, and LmMK-HATi. When tetracycline was added to the media to induce over-expression, a final concentration of 1 μg/mL was used. Cells were counted each day and passaged when the density was between 2 and 3 × 106 (normally every second day).
Over expressing T. brucei and L. major MK genes in procyclic form T. brucei
Mid-log T. brucei TbMK-HATi, LmMK-HATi and wild type procyclic form cells which had been grown in the presence of tetracycline for one day, were harvested by centrifugation (800 g, 10 min), the cell pellets were washed in TDB buffer (25 mM KCl, 400 mM NaCl, 5 mM MgSO4, 100 mM Na2HPO4, NaH2PO4, pH 7.4, 100 mM glucose) and used either for western blotting or immunoprecipitation (Figure 2). For western blotting the cells (2 × 106) were lysed and denatured directly in hot sample buffer and run on an SDS/10 % polyacrylamide gel and transferred to an ECL-Nylon membrane (Amersham). After blocking overnight in PBS-5 % skim milk powder, protein was detected using the primary monoclonal antibody; rat anti-HA (Roche), followed by a secondary horseradish peroxidase conjugated rabbit anti-rat immunoglobulin (Jackson) and ECL western detection reagents (Amersham). For immunoprecipitation, cells (1 × 108) were lysed in 1 mL of Tris-HCl (20 mM pH 7.0), NaCl (0.15 M) and NP-40 (1%). After agitating for 30 min the cell ghosts were spun down and the supernatant added to 100 μL of equilibrated anti-HA affinity matrix (Roche) and agitated at 4°C overnight. The beads were spun down and washed twice with 500 μL of lysis buffer and resuspended in 100 μL of potassium phosphate buffer (0.1 M) and stored at -20°C until required.
MK assays and binding studies
A coupled spectroscopic assay was performed according to a published protocol with varying concentrations of recombinant Lm MK; Mj MK provided the positive control . Briefly, in a 1 mL cuvette, 0.1 M Tris·HCl pH 7.5, 5 mM MgCl2, 0.5 M phosphoenolpyruvate, 0.1 M NADH, 0.1 M ATP, 0.1 M (R/S)-mevalonic acid, 40 U pyruvate kinase and 27.5 U lactate dehydrogenase were incubated at 25°C. The enzyme activity was monitored at 340 nm for 300 seconds (Shimadzu UV-1601).
In a radioactive assay, 0.1 M KH2PO4/K2HPO4 pH 7.0, 0.1 M ATP, 10 μM reduced glutathione, 5 μM MgCl2, 833 μM [3H] (R)-MVA (60 Ci/μmol) (ARC) with either 31.0 μM Lm MK (approximately 115 μg) or with 20 μM of immunoprecipitate α-HA Lm MK or Tb MK (equivalent to 2 × 107 procyclic cells) in a volume of 100 μL were incubated for 2 h at 30°C. The reaction was quenched by heat inactivation at 100°C for 2 min, the protein was spun down and the supernatant applied to a 30 cm strip of Whatman paper. The pellet was mixed with 20 μL water, centrifuged and the washing added to the Whatman paper. Unreacted [3H] (R)-MVA was separated from the [3H] (R)-MVA 5-phosphate product by descending thin-layer chromatography using propan-1-ol:NH3:H2O (6:2:1). The same amount of [3H] (R)-MVA provided a negative control. [3H] (R)-MVA and [3H] (R)-MVA 5-phosphate were localized using a Bioscan AR-200 linear analyzer at a distance of 4 cm or 23.5 cm from the origin, respectively. The Whatman paper was cut into 1 cm strips and the radioactivity per strip quantified by liquid scintillation counting. The combined counts corresponding to [3H] (R)-MVA 5-phosphate were then compared with the initial amount of [3H] (R)-MVA utilized in the enzymatic reaction.
The potential association of TNP-ATP (Molecular Probes) with Lm MK was investigated following a published protocol . Measurements were carried out in 100 mM Tris-HCl pH 7.0, 100 mM NaCl and 10 mM MgCl2 at enzyme concentrations of 3.2 μM or 12.8 μM, respectively. TNP-ATP concentration was varied between 15 μM and 152 μM. For measurements, (Varian Cary Eclipse Fluorescence Spectrometer) the excitation wavelength was 408 nm and the emission spectra obtained by scanning 500 to 600 nm. The positive control was binding of TNP-ATP to T. brucei MDD (data not shown).
Quaternary structure investigation
The possibility of an oligomeric assembly was investigated by gel filtration and analytical ultracentrifugation. The gel filtration column HiLoad 16/60 Superdex™ 200 prep grade (GE Healthcare) was calibrated with the Gel Filtration LMW Calibration Kit (GE Healthcare). The Lm MK eluted from the column at a volume of 92 ml, which corresponds to a molecular mass of approximately 35 kDa (data not shown).
A sample of Lm MK, (0.5 mg/mL in 10 mM Tris·HCl pH, 20 mM NaCl and 1 mM tris(2-carboxyethyl)phosphine hydrochloride) was used in sedimentation velocity experiments performed at a wavelength of 280 nm, at 45,000 rpm and 20°C, using a Beckman Coulter XL-i analytical ultracentrifuge. The sample was centrifuged with A280 measured every 5 min over a period of 15 hours. The resultant data were analysed using the program SEDFIT . The sedimentation co-efficient that was obtained, 2.97 s, corresponds to a mass of approximately 33.6 kDa.
Lm MK crystallized using hanging drop vapor diffusion at 18°C. Drops were assembled from 2 μL reservoir (1.15 M sodium citrate pH 6.2) and 2 μL protein solution (7.5 mg/mL protein, 3 mM AMPPNP and 6 mM (R/S)-MVA). The enantiomeric mixture of the substrate was prepared from RS-mevalonolactone (Sigma-Aldrich) according to literature methods . Thin monoclinic plates (0.4 mm × 0.2 mm × < 0.1 mm) grew after approximately one week. Crystals of the native protein in complex with (R)-MVA formed under similar conditions with 25 mM AMPPNP, 50 mM (R/S)-MVA and 10 mM MgCl2 in the drop.
A crystal of SeMet Lm MK was flash cooled directly in a stream of gaseous nitrogen at 100 K and diffraction data were measured on beam-line ID14-4 at the European Synchrotron Radiation Facility (Grenoble, France). A fluorescence scan was used to determine the Se K absorption edge wavelength for data collection, λ = 0.97945 Å, and data recorded using a Q315r ADSC CCD detector. Data for the binary substrate complex were collected using a Rigaku 007 Micromax rotating-anode generator (Cu Kα, λ = 1.5418 Å) operating at 30 mA and 40 kV, coupled to a R-AXIS IV++ dual image plate system. All data were processed and scaled with Denzo/Scalepack .
We were unable to solve the Lm MK structure by molecular replacement and therefore adopted a single wavelength anomalous dispersion approach. Data to 2.0 Å identified six Se positions out of eight (SOLVE) and the correct enantiomorph gave a figure-of-merit of 0.38 and a Z-Score of 40. After density modification (RESOLVE ) the figure-of-merit increased to 0.72 with a correlation coefficient of 0.75. Automated model building (ARP/wARP ) constructed an initial model of 531 (out of 658) residues and the structure was refined (REFMAC5 ) to an R- factor/R-work of 26.2 % and an R- free of 32.4 % of 1.75 Å employing strict NCS restraints. 5% of the data were set aside for the calculation of R- free. Additional residues and water molecules were placed manually into the electron density with COOT  interspersed by refinement with REFMAC5. Towards the end of the refinement, the NCS restraints were released. The quality of the structure was assessed with PROCHECK . All residues are situated in most favored or additionally allowed regions of the Ramachandran plot apart from His25 in both molecules. Three residues at the C-terminus are disordered and not included in the structure.
The crystal structure of SeMet Lm MK was used in molecular replacement calculations (MOLREP ) to provide the initial model for the substrate complex. The correlation coefficient of the first model was 0.67 and R- work 33.1 %. The electron density clearly indicated the presence of (R)-MVA in molecule A of the asymmetric unit. The refinement process was completed in a similar fashion to SeMet Lm MK. Statistics are presented in Table 1. Figures were prepared with Chemdraw (Adept Scientific), PyMOL§ and ALINE (C. S. Bond, personal communication). Coordinates and structure factors have been deposited in the Protein Data Bank [PDB:2HFS and PDB:2HFU].
# Z-score measures the statistical significance of the best alignment and typically, dissimilar structures present a Z-score less than 2.0.
§ DeLano, W. L. (2002) The PyMOL Molecular Graphics System, DeLano Scientific, San Carlos, CA, USA.
adenosine 5'-(β,γ-imido) triphosphate
mevalonate 5-diphosphate decarboxylase
- Lm MK:
Leishmania major mevalonate kinase
- Mj MK:
Methanococcus jannaschii mevalonate kinase
Protein Data Bank
root mean square deviation
- Rn MK:
Rattus norvegicus mevalonate kinase
single-wavelength anomalous dispersion
- Tb MK:
Trypanosoma brucei mevalonate kinase
- Tc MK:
Trypanosoma cruzi mevalonate kinase
2'(3')-O-(2,4,6-trinitrophenyl) adenosine 5'-triphosphate.
This research was supported by the German Academic Exchange Service (DAAD), the Wellcome Trust (TKS and WNH as Trust Senior Research fellows), the Biotechnology and Biological Science Research Council (Structural Proteomics of Rational Targets) and the European Synchrotron Radiation Facility. We thank Ding Li and colleagues who provided Mj MK, staff at the synchrotron, Charles Bond, Emma Byres and Magnus Alphey for advice.
- Edwards PA, Ericsson J: Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 1999, 68: 157–185. 10.1146/annurev.biochem.68.1.157View ArticlePubMedGoogle Scholar
- Eisenreich W, Bacher A, Arigoni D, Rohdich F: Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol Life Sci 2004, 61(12):1401–1426. 10.1007/s00018-004-3381-zView ArticlePubMedGoogle Scholar
- Rohmer M, Grosdemange-Billiard C, Seemann M, Tritsch D: Isoprenoid biosynthesis as a novel target for antibacterial and antiparasitic drugs. Curr Opin Investig Drugs 2004, 5(2):154–162.PubMedGoogle Scholar
- Kuzuyama T: Mevalonate and nonmevalonate pathways for the biosynthesis of isoprene units. Biosci Biotechnol Biochem 2002, 66(8):1619–1627. 10.1271/bbb.66.1619View ArticlePubMedGoogle Scholar
- Coppens I, Courtoy PJ: The mevalonate pathway in parasitic protozoa and helminths. Exp Parasitol 1996, 82(1):76–85. 10.1006/expr.1996.0011View ArticlePubMedGoogle Scholar
- Barrett MP, Burchmore RJ, Stich A, Lazzari JO, Frasch AC, Cazzulo JJ, Krishna S: The trypanosomiases. The Lancet 2003, 362: 1469–1480. 10.1016/S0140-6736(03)14694-6View ArticleGoogle Scholar
- Herwaldt BL: Leishmaniasis. The Lancet 1999, 354: 1191–1199. 10.1016/S0140-6736(98)10178-2View ArticleGoogle Scholar
- Yang D, Shipman LW, Roessner CA, Scott AI, Sacchettini JC: Structure of the Methanococcus jannaschii mevalonate kinase a member of the GHMP kinase superfamily. J Biol Chem 2002, 277(11):9462–9467. 10.1074/jbc.M110787200View ArticlePubMedGoogle Scholar
- Fu Z, Wang M, Potter D, Miziorko HM, Kim JJ: The structure of a binary complex between a mammalian mevalonate kinase and ATP: insights into the reaction mechanism and human inherited disease. J Biol Chem 2002, 277(20):18134–18142. 10.1074/jbc.M200912200View ArticlePubMedGoogle Scholar
- Potter D, Miziorko HM: Identification of catalytic residues in human mevalonate kinase. J Biol Chem 1997, 272(41):25449–25454. 10.1074/jbc.272.41.25449View ArticlePubMedGoogle Scholar
- Bork P, Sander C, Valencia A: Convergent evolution of similar enzymatic function on different protein folds: the hexokinase ribokinase and galactokinase families of sugar kinases. Protein Sci 1993, 2(1):31–40.PubMed CentralView ArticlePubMedGoogle Scholar
- Miallau L, Alphey MS, Kemp LE, Leonard GA, McSweeney SM, Hecht S, Bacher A, Eisenreich W, Rohdich F, Hunter WN: Biosynthesis of isoprenoids: crystal structure of 4-diphosphocytidyl-2C-methyl-D-erythritol kinase. Proc Natl Acad Sci USA 2003, 100(16):9173–9178. 10.1073/pnas.1533425100PubMed CentralView ArticlePubMedGoogle Scholar
- Bonanno JB, Edo C, Eswar N, Pieper U, Romanowski MJ, Ilyin V, Gerchman SE, Kycia H, Studier FW, Sali A, Burley SK: Structural genomics of enzymes involved in sterol/isoprenoid biosynthesis. Proc Natl Acad Sci USA 2001, 98(24):12896–12901. 10.1073/pnas.181466998PubMed CentralView ArticlePubMedGoogle Scholar
- Daugherty M, Vonstein V, Overbeek R, Osterman A: Archaeal shikimate kinase a new member of the GHMP-kinase family. J Bacteriol 2001, 183(1):292–300. 10.1128/JB.183.1.292-300.2001PubMed CentralView ArticlePubMedGoogle Scholar
- Potter D, Wojnar JM, Narasimhan C, Miziorko HM: Identification and functional characterization of an active-site lysine in mevalonate kinase. J Biol Chem 1997, 272(9):5741–5746. 10.1074/jbc.272.9.5741View ArticlePubMedGoogle Scholar
- Cho YK, Rios SE, Kim JJ, Miziorko HM: Investigation of invariant serine/threonine residues in mevalonate kinase. Tests of the functional significance of a proposed substrate binding motif and a site implicated in human inherited disease. J Biol Chem 2001, 276(16):12573–12578. 10.1074/jbc.M011478200View ArticlePubMedGoogle Scholar
- Chu X, Li D: Expression purification and characterization of His20 mutants of rat mevalonate kinase. Protein Expr Purif 2003, 32(1):75–82. 10.1016/S1046-5928(03)00221-3View ArticlePubMedGoogle Scholar
- Chu X, Liu X, Yau M, Leung YC, Li D: Expression and purification of Arg196 and Lys272 mutants of mevalonate kinase from Methanococcus jannaschii . Protein Expr Purif 2003, 30(2):210–218. 10.1016/S1046-5928(03)00101-3View ArticlePubMedGoogle Scholar
- Voynova NE, Rios SE, Miziorko HM: Staphylococcus aureus mevalonate kinase: isolation and characterization of an enzyme of the isoprenoid biosynthetic pathway. J Bacteriol 2004, 186(1):61–67. 10.1128/JB.186.1.61-67.2004PubMed CentralView ArticlePubMedGoogle Scholar
- Cheek S, Zhang H, Grishin NV: Sequence and structure classification of kinases. J Mol Biol 2002, 320(4):855–881. 10.1016/S0022-2836(02)00538-7View ArticlePubMedGoogle Scholar
- Holm L, Sander C: Mapping the protein universe. Science 1996, 273: 595–603. 10.1126/science.273.5275.595View ArticlePubMedGoogle Scholar
- Zhou T, Daugherty M, Grishin NV, Osterman AL, Zhang H: Structure and mechanism of homoserine kinase: prototype for the GHMP kinase superfamily. Structure Fold Des 2000, 8(12):1247–1257. 10.1016/S0969-2126(00)00533-5View ArticlePubMedGoogle Scholar
- Krishna SS, Zhou T, Daugherty M, Osterman A, Zhang H: Structural basis for the catalysis and substrate specificity of homoserine kinase. Biochemistry 2001, 40(36):10810–10818. 10.1021/bi010851zView ArticlePubMedGoogle Scholar
- Romanowski MJ, Bonanno JB, Burley SK: Crystal structure of the Streptococcus pneumoniae phosphomevalonate kinase a member of the GHMP kinase superfamily. Proteins 2002, 47(4):568–571. 10.1002/prot.10118View ArticlePubMedGoogle Scholar
- Hedl M, Rodwell VW: Enterococcus faecalis mevalonate kinase. Protein Sci 2004, 13(6):687–693. 10.1110/ps.03367504PubMed CentralView ArticlePubMedGoogle Scholar
- Houten SM, Frenkel J, Rijkers GT, Wanders RJ, Kuis W, Waterham HR: Temperature dependence of mutant mevalonate kinase activity as a pathogenic factor in hype R -IgD and periodic fever syndrome. Hum Mol Genet 2002, 11(25):3115–3124. 10.1093/hmg/11.25.3115View ArticlePubMedGoogle Scholar
- Beytia E, Dorsey JK, Marr J, Cleland WW, Porter JW: Purification and mechanism of action of hog liver mevalonic kinase. J Biol Chem 1970, 245(20):5450–5458.PubMedGoogle Scholar
- Wirtz E, Leal S, Ochatt C, Cross GAM: A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei . Mol Biochem Parasitol 1999, 99(1):89–101. 10.1016/S0166-6851(99)00002-XView ArticlePubMedGoogle Scholar
- Brun R, Schoenenberger M: Cultivation and in vitro cloning or procyclic culture forms of Trypanosoma brucei in a semi-defined medium. Acta Trop 1979, 36(3):289–292.PubMedGoogle Scholar
- Wirtz E, Hartmann C, Clayton C: Gene expression mediated by bacteriophage T3 and T7 RNA polymerases in transgenic trypanosomes. Nucleic Acids 1994, 22(19):3887–3894. 10.1093/nar/22.19.3887View ArticleGoogle Scholar
- Schuck P: Size distribution analysis of macromolecules by sedimentation velocity ultracentrifugation and Lamm equation modelling. Biophysical J 2000, 78(3):1606–1619.View ArticleGoogle Scholar
- Skilleter DN, Kekwick RG: An improved ion-exchange procedure for the chromatography of the metabolites of mevalonate. Anal Biochem 1967, 20(1):171–180. 10.1016/0003-2697(67)90275-8View ArticlePubMedGoogle Scholar
- Otwinowski Z, Minor W: Processing of X-ray diffraction data in oscillation mode. Methods Enzymol 1996, 276: 307–326.View ArticleGoogle Scholar
- Terwilliger TC, Berendzen J: Automated MAD and MIR structure solution. Acta Crystallog 1999, D55(4):849–861.Google Scholar
- Terwilliger TC: Maximum-likelihood density modification. Acta Crystallog 2000, D56(8):965–972.Google Scholar
- Morris RJ, Perrakis A, Lamzin VS: ARP/wARP and automatic interpretation of protein electron density maps. Methods Enzymol 2003, 374: 229–244.View ArticlePubMedGoogle Scholar
- Murshudov GN, Vagin AA, Dodson EJ: Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog 1997, D53(3):240–255.Google Scholar
- Emsley P, Cowtan K: Coot: model-building tools for molecular graphics. Acta Crystallog 2004, D60(12):2126–2132.Google Scholar
- Laskowski RA, MacArthur MW, Moss DS, Thornton JM: PROCHECK: a program to check the stereochemical properties of protein structures. J Appl Crystallog 1993, 26(2):283–291. 10.1107/S0021889892009944View ArticleGoogle Scholar
- Vagin A, Teplyakov A: MOLREP: an automated program for molecular replacement. J Appl Crystallog 1997, 30(6):1022–1025. 10.1107/S0021889897006766View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.